Presence of Sub-Clinical Atrial Fibrillation using an implantable cardiac monitor in patients with cardiovascular risk factors (ASSERT II) - ASSERT II

Population Health Research Institute of Hamilton Health Sciences0 个研究点目标入组 150 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Patients will be eligible for inclusion if they provide written consent and meet both of the following:
•1. Age * 65, plus:
•a. CHA2DS2-VASc score * 2
•b. Obstructive sleep apnea (documented by polysomnography, ambulatory oximetry, positive Berlin Questionnaire or requiring the use of CPAP/BiPAP)
•c. BMI > 30;AND;2. Echocardiographic or biochemical evidence of increased risk of AF:
•a. Left atrial enlargement on a clinical echocardiograph at any time prior to enrolment (defined as LA volume * 58 ml or LA diameter of * 4.4 cm)
•b. Serum NT-ProBNP * 290 pg/mL

•1. Previously documented history of atrial fibrillation or atrial flutter, with an episode duration of at least 5 minutes
•2. Current chronic treatment with oral anticoagulation (i.e., those on peri-operative prophylaxis would be eligible)
•3. Patient with existing implanted pacemaker or defibrillator
•4. Definitive plan for cardiac surgery in the next 6 months (patients who are having coronary angiography with a possibility of cardiac surgery are still eligible)

发起方

Population Health Research Institute of Hamilton Health Sciences